Updated follow-up of the Alta Study, a phase 1/2, open label, adaptive, dose-ranging study to assess the safety and tolerability of SB-525 gene therapy in adult patients with severe hemophilia A [abstract] - Konkle, B A; Stine, K; Visweshwar, N (Blood, 2019)
(Supplement 1):